Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC
October 26th 2020The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.
MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases
October 23rd 2020The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential therapies to treat brain metastases and those with cancers refractory to available therapies.